Grant of Options

Oxford Biomedica PLC

04 October 2023

 

Grant of options

London, UK - 04 October 2023: Oxford Biomedica plc ("Oxford Biomedica" or "the Company") (LSE: OXB) announces that on 04 October 2023 nil-cost share options over ordinary shares of 50 pence each in the Company were granted under the Oxford Biomedica 2015 Deferred Bonus Plan ("DBP") and the Oxford Biomedica 2015 Long Term Incentive Plan ("LTIP").

2023 LTIP and 2022 DBP Awards

Name of individual	Title	Number of shares subject to the 2022 DBP award	Number of shares subject to the 2023 LTIP award	Total shares over which options now held	Percentage of current issued share capital under option
Frank Mathias	Chief Executive Officer	-	323,178	323,178	0.334%
Stuart Paynter	Chief Financial Officer	63,869	142,469	538,211	0.556%
Sebastien Ribault	Chief Commercial Officer		66,903	66,903	0.069%
Mark Caswell	Site Head US Operations		74,172	74,172	0.077%
Lisa James	Chief People Officer	15,887	39,670	99,989	0.103%
James Miskin	Chief Technical Officer	32,189	56,262	215,035	0.222%
Kyriacos Mitrophanous	Chief Scientific Officer	35,256	57,906	277,856	0.287%
Madduri Ravi Rao	Chief Medical Officer	21,129	50,135	131,400	0.136%
Matthew Treagus	Chief Information Officer and Chief of Staff	32,468	54,433	143,648	0.148%
Natalie Walter	General Counsel	27,897	48,069	167,244	0.173%

Under the terms of the DBP plan, the DBP awards will become exercisable as to one third of the shares subject to each award on each of the first three anniversaries of the grant date.

In line with best practice and current investor guidance the quantum of the 2023 LTIP to Frank Mathias was scaled back from 200% of salary to 160% of salary and for Stuart Paynter the quantum of the 2023 LTIP was scaled back by 30% from 175% of salary to 122.5% of salary. The quantum of 2023 LTIP granted to other new members of SET was scaled back by 20%, all other members of the set had their awards scaled back by 30%

The LTIP awards are subject to performance conditions. As set out in the 2022 Directors' Remuneration Report, the performance condition is based on TSR (40% of the award, assessed over the three years from grant); revenue growth (40% of the award, assessed over financial years 2023, 2024 and 2025) and strategic milestones (20% of the award). Details of the measures are included in the 2022 Directors' Remuneration Report, other than as regards the strategic milestones, which are commercially sensitive and will be disclosed in due course.

The LTIP awards granted to Frank Mathias and Stuart Paynter will "vest" following the assessment of the performance condition, but will only be "released" so that they can be exercised following the end of a further two year holding period. The 2023 awards granted to other participants will vest and be released following the assessment of the performance condition.

The Notification of Dealing Forms set out below are provided in accordance with the requirements of the EU Market Abuse Regulation.

Notification of Dealing Form

1.	Details of the Person Discharging Managerial Responsibility ("PDMR")/person closely associated with them ("PCA")
a)	Name	Frank Mathias
2.	Reason for the notification
a)	Position/status	Chief Executive Officer
b)	Initial notification/ amendment	Initial Notification
3.	Details of the Issuer
a)	Name	Oxford Biomedica plc
b)	LEI code	213800S1GVQNXQ15K851
4.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)	Description of the financial instrument Identification code	Ordinary Shares of 50 pence each ISIN: GB00BDFBVT43
b)	Nature of the transaction	Grant of awards over Ordinary Shares under the Company's Long Term Incentive Plan. No consideration was paid for the grant of awards.
c)	Price(s) and volumes(s)	2023 LTIP Award Price Volume Nil 323,178
d)	Aggregated information -    Aggregate volume -    Price	Awards granted over 323,178 shares in total N/A
e)	Date of the transaction	2023-10-04
f)	Place of the transaction	Outside of trading venue

1.	Details of the Person Discharging Managerial Responsibility ("PDMR")/person closely associated with them ("PCA")
a)	Name	Stuart Paynter
2.	Reason for the notification
a)	Position/status	Chief Financial Officer
b)	Initial notification/ amendment	Initial Notification
3.	Details of the Issuer
a)	Name	Oxford Biomedica plc
b)	LEI code	213800S1GVQNXQ15K851
4.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)	Description of the financial instrument Identification code	Ordinary Shares of 50 pence each ISIN: GB00BDFBVT43
b)	Nature of the transaction	Grant of awards over Ordinary Shares under the Company's Long Term Incentive Plan and Deferred Bonus Plan. No consideration was paid for the grant of awards.
c)	Price(s) and volumes(s)	2023 LTIP Award Price Volume Nil 142,469 2022 DBP Award Price Volume Nil 63,869
d)	Aggregated information -    Aggregate volume -    Price	Awards granted over 206,338 shares in total N/A
e)	Date of the transaction	2023-10-04
f)	Place of the transaction	Outside of trading venue

1.	Details of the Person Discharging Managerial Responsibility ("PDMR")/person closely associated with them ("PCA")
a)	Name	Sebastien Ribault
2.	Reason for the notification
a)	Position/status	Chief Commercial Officer
b)	Initial notification/ amendment	Initial Notification
3.	Details of the Issuer
a)	Name	Oxford Biomedica plc
b)	LEI code	213800S1GVQNXQ15K851
4.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)	Description of the financial instrument Identification code	Ordinary Shares of 50 pence each ISIN: GB00BDFBVT43
b)	Nature of the transaction	Grant of awards over Ordinary Shares under the Company's Long Term Incentive Plan. No consideration was paid for the grant of awards.
c)	Price(s) and volumes(s)	2023 LTIP Award Price Volume Nil 66,903
d)	Aggregated information -    Aggregate volume -    Price	Awards granted over 66,903 shares in total N/A
e)	Date of the transaction	2023-10-04
f)	Place of the transaction	Outside of trading venue

1.	Details of the Person Discharging Managerial Responsibility ("PDMR")/person closely associated with them ("PCA")
a)	Name	Mark Caswell
2.	Reason for the notification
a)	Position/status	Site Head of US Operations
b)	Initial notification/ amendment	Initial Notification
3.	Details of the Issuer
a)	Name	Oxford Biomedica plc
b)	LEI code	213800S1GVQNXQ15K851
4.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)	Description of the financial instrument Identification code	Ordinary Shares of 50 pence each ISIN: GB00BDFBVT43
b)	Nature of the transaction	Grant of awards over Ordinary Shares under the Company's Long Term Incentive Plan. No consideration was paid for the grant of awards.
c)	Price(s) and volumes(s)	2023 LTIP Award Price Volume Nil 74,172
d)	Aggregated information -    Aggregate volume -    Price	Awards granted over 74,172 shares in total N/A
e)	Date of the transaction	2023-10-04
f)	Place of the transaction	Outside of trading venue

1.	Details of the Person Discharging Managerial Responsibility ("PDMR")/person closely associated with them ("PCA")
a)	Name	Lisa James
2.	Reason for the notification
a)	Position/status	Chief People Officer
b)	Initial notification/ amendment	Initial Notification
3.	Details of the Issuer
a)	Name	Oxford Biomedica plc
b)	LEI code	213800S1GVQNXQ15K851
4.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)	Description of the financial instrument Identification code	Ordinary Shares of 50 pence each ISIN: GB00BDFBVT43
b)	Nature of the transaction	Grant of awards over Ordinary Shares under the Company's Long Term Incentive Plan and Deferred Bonus Plan. No consideration was paid for the grant of awards.
c)	Price(s) and volumes(s)	2023 LTIP Award Price Volume Nil 39,670 2022 DBP Award Price Volume Nil 15,887
d)	Aggregated information -    Aggregate volume -    Price	Awards granted over 55,557 shares in total N/A
e)	Date of the transaction	2023-10-04
f)	Place of the transaction	Outside of trading venue

1.	Details of the Person Discharging Managerial Responsibility ("PDMR")/person closely associated with them ("PCA")
a)	Name	James Miskin
2.	Reason for the notification
a)	Position/status	Chief Technical Officer
b)	Initial notification/ amendment	Initial Notification
3.	Details of the Issuer
a)	Name	Oxford Biomedica plc
b)	LEI code	213800S1GVQNXQ15K851
4.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)	Description of the financial instrument Identification code	Ordinary Shares of 50 pence each ISIN: GB00BDFBVT43
b)	Nature of the transaction	Grant of awards over Ordinary Shares under the Company's Long Term Incentive Plan and Deferred Bonus Plan. No consideration was paid for the grant of awards.
c)	Price(s) and volumes(s)	2023 LTIP Award Price Volume Nil 56,262 2022 DBP Award Price Volume Nil 32,189
d)	Aggregated information -    Aggregate volume -    Price	Awards granted over 88,451 shares in total N/A
e)	Date of the transaction	2023-10-04
f)	Place of the transaction	Outside of trading venue

1.	Details of the Person Discharging Managerial Responsibility ("PDMR")/person closely associated with them ("PCA")
a)	Name	Kyriacos Mitrophanous
2.	Reason for the notification
a)	Position/status	Chief Scientific Officer
b)	Initial notification/ amendment	Initial Notification
3.	Details of the Issuer
a)	Name	Oxford Biomedica plc
b)	LEI code	213800S1GVQNXQ15K851
4.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)	Description of the financial instrument Identification code	Ordinary Shares of 50 pence each ISIN: GB00BDFBVT43
b)	Nature of the transaction	Grant of awards over Ordinary Shares under the Company's Long Term Incentive Plan and Deferred Bonus Plan. No consideration was paid for the grant of awards.
c)	Price(s) and volumes(s)	2023 LTIP Award Price Volume Nil 57,906 2022 DBP Award Price Volume Nil 35,256
d)	Aggregated information -    Aggregate volume -    Price	Awards granted over 93,162 shares in total N/A
e)	Date of the transaction	2023-10-04
f)	Place of the transaction	Outside of trading venue

1.	Details of the Person Discharging Managerial Responsibility ("PDMR")/person closely associated with them ("PCA")
a)	Name	Madduri Rao
2.	Reason for the notification
a)	Position/status	Chief Medical Officer
b)	Initial notification/ amendment	Initial Notification
3.	Details of the Issuer
a)	Name	Oxford Biomedica plc
b)	LEI code	213800S1GVQNXQ15K851
4.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)	Description of the financial instrument Identification code	Ordinary Shares of 50 pence each ISIN: GB00BDFBVT43
b)	Nature of the transaction	Grant of awards over Ordinary Shares under the Company's Long Term Incentive Plan and Deferred Bonus Plan. No consideration was paid for the grant of awards.
c)	Price(s) and volumes(s)	2023 LTIP Award Price Volume Nil 50,135 2022 DBP Award Price Volume Nil 21,129
d)	Aggregated information -    Aggregate volume -    Price	Awards granted over 71,264 shares in total N/A
e)	Date of the transaction	2023-10-04
f)	Place of the transaction	Outside of trading venue

1.	Details of the Person Discharging Managerial Responsibility ("PDMR")/person closely associated with them ("PCA")
a)	Name	Matthew Treagus
2.	Reason for the notification
a)	Position/status	Chief Information Officer and Chief of Staff
b)	Initial notification/ amendment	Initial Notification
3.	Details of the Issuer
a)	Name	Oxford Biomedica plc
b)	LEI code	213800S1GVQNXQ15K851
4.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)	Description of the financial instrument Identification code	Ordinary Shares of 50 pence each ISIN: GB00BDFBVT43
b)	Nature of the transaction	Grant of awards over Ordinary Shares under the Company's Long Term Incentive Plan and Deferred Bonus Plan. No consideration was paid for the grant of awards.
c)	Price(s) and volumes(s)	2023 LTIP Award Price Volume Nil 54,433 2022 DBP Award Price Volume Nil 32,468
d)	Aggregated information -    Aggregate volume -    Price	Awards granted over 86,901 shares in total N/A
e)	Date of the transaction	2023-10-04
f)	Place of the transaction	Outside of trading venue

1.	Details of the Person Discharging Managerial Responsibility ("PDMR")/person closely associated with them ("PCA")
a)	Name	Natalie Walter
2.	Reason for the notification
a)	Position/status	General Counsel
b)	Initial notification/ amendment	Initial Notification
3.	Details of the Issuer
a)	Name	Oxford Biomedica plc
b)	LEI code	213800S1GVQNXQ15K851
4.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)	Description of the financial instrument Identification code	Ordinary Shares of 50 pence each ISIN: GB00BDFBVT43
b)	Nature of the transaction	Grant of awards over Ordinary Shares under the Company's Long Term Incentive Plan and Deferred Bonus Plan. No consideration was paid for the grant of awards.
c)	Price(s) and volumes(s)	2023 LTIP Award Price Volume Nil 48,069 2022 DBP Award Price Volume Nil 27,897
d)	Aggregated information -    Aggregate volume -    Price	Awards granted over 75,966 shares in total N/A
e)	Date of the transaction	2023-10-04
f)	Place of the transaction	Outside of trading venue

-Ends-

For further information, please contact:
Oxford Biomedica plc: Natalie Walter, Company Secretary	Tel: [phone]

About Oxford Biomedica

Oxford Biomedica (LSE: OXB) is a quality and innovation-led cell and gene therapy CDMO with a mission to enable its clients to deliver life changing therapies to patients around the world.

One of the original pioneers in cell and gene therapy, the Company has more than 25 years of experience in viral vectors; the driving force behind the majority of gene therapies. The Company collaborates with some of the world's most innovative pharmaceutical and biotechnology companies, providing viral vector development and manufacturing expertise in lentivirus, adeno-associated virus (AAV) and adenoviral vectors. Oxford Biomedica's world-class capabilities span from early-stage development to commercialisation. These capabilities are supported by robust quality-assurance systems, analytical methods and depth of regulatory expertise.

Oxford Biomedica, a FTSE4Good constituent, is headquartered in Oxford, UK. It has locations across Oxfordshire, UK and near Boston, MA, US. Learn more at www.oxb.com, www.oxbsolutions.com, and follow us on LinkedIn and YouTube.

 

END